In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations.
Although the pCPA Negotiation Guidelines report outlined how manufacturers should deal with the pCPA pre-negotiation, negotiation and post-negotiation stages, it did not provide guidance on understanding the payers’ environment and best practices to deal with negotiations. To address this gap and provide more insights on trends and outlook, PDCI has developed a new report entitled pan-Canadian Pharmaceutical Alliance: Context, Best Practices, Trends and Outlook (see URL below). The purpose of this report is to:
- provide context on process, structure, negotiations, and agreements;
- outline strategic and tactical best practices for engaging with the pCPA;
- clarify some of the recent emerging trends; and
- offer an outlook as to how the environment may evolve in the future.
In addition, PDCI has developed an infographic which details 10 strategic/tactical considerations for manufacturers as they engage with the pCPA (see URL links below).
Please do not hesitate to contact Courtney (Courtney.Abunassar@pdci.ca) if you have any questions on the attached.